Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Prepares For Push Into MENA Oncology Biologics Market

Executive Summary

Having enjoyed some success in the Middle East and North Africa region with its Remsima infliximab biosimilar for autoimmune disorders, Hikma is lining up launches of both rituximab and trastuzumab into the region’s oncology arena.

You may also be interested in...



Hikma Searches For Strategic ‘Fourth Leg’

To secure long-term growth, Hikma CEO Siggi Olafsson is seeking to add a fourth strategic pillar to its global generic Injectables, US non-injectable Generics and Middle East and North Africa Branded business segments.

Portuguese Plant Opens Up Prospects For Hikma To Expand In Europe

Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.

Remsima broadens access

Hikma says it has considerably broadened access to infliximab in Morocco by introducing its Remsima biosimilar early last year. The Jordanian firm claims to have helped increase the size of the local market by about 50% to 11,000 vials per year whilst raising Remsima’s market share to more than 75%. “This example demonstrates how we grow our business and we are not limited to taking market share from the originator,” commented Hikma’s chief executive officer Siggi Olafsson.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel